Takeda Rozerem Clinical Significance Debated In FDA Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency revieweres questioned the insomnia drug’s failure to meet subjective secondary endpoints despite efficacy on objective sleep measurements.